Since the British left the EU, pessimism in the pharmaceutical industry in the UK has been particularly high. However, it is greater than the negative effects caused by the Corona pandemic, according to an analysis by the consulting firm Global Data.
Global Data initiated a survey of 150 healthcare industry respondents, finding among industry professionals interviewed worldwide that fear and uncertainty are more related to Brexit than to the Covid 19 infection event, which is likely to disrupt supply chains only in the short term.
However, it was difficult for Global Data analysts to track exactly which factors had an adverse impact and how. What is clear, however, is that border controls have negatively impacted limited trade with Europe and by new rules on both sides. This mainly affects areas such as research and development and logistics and supply chains, Global Data experts, including Elton Kwok, who accompanied the research, have found. Even if the no-deal Brexit did not materialize, the respondents fear, above all, more bureaucracy and higher costs in these sectors. Even in the long term, after the negotiations are concluded, instability and lack of transparency are also expected. The pharmaceutical industry is even concerned that there will be long-term negative effects in manufacturing, financing, recruitment, and regulations.
Source: www.pharmazeutische-zeitung.de